← All stocks

Repligen Corp

RGENBiotechnologyLatest filing used: 2026-10-30Filings on SEC EDGAR ↗

Above fair value Strong balance sheet Fast grower Flags raised

Fair value per share

$23.84

from SEC filings only

Last close

$167.89

Nov 13, 2026

604.3% above fair value

Margin of safety price
$17.88
25% below fair value
Stress case
$15.80
if things go badly

Its filings point to about $23.84 a share, most likely between $17.14 and $32.41.

Where it sits

Not ranked: rough estimate.

Counts the 653 stocks that have both a value and a close as of Nov 13. Positions are squeezed so the biggest gaps fit.

The short case

In favour

  • It turns about 18% of its sales into cash in a typical year.
  • Sales have grown about 15% a year over the last five years.
  • It holds more cash than debt.

Against

  • Its last close is about 604% above what its filings say it is worth.
  • This estimate is less than a third of what outside investors' shares were worth on the company's cover page (June 30, 2025): the filings alone probably miss what investors expect (faster growth, margins still changing, or a business that is changing).
  • Earnings per share fell over the last 12 months.

Written automatically from the filings, by the same rules for every company. Not a recommendation.

Five areas

12 of 25 checks passedStrong in 2 of 5 areas

GrowthWeak · 2 of 5
  • Revenue up 5%+ a year over 3 years (not passed)
  • Revenue up 5%+ a year over 5 years (passed)
  • Earnings per share up 5%+ a year over 5 years (not passed)
  • Revenue up over the last 12 months (passed)
  • Earnings per share up over the last 12 months (not passed)
ProfitabilityWeak · 1 of 5
  • Return on equity of 15%+ (last 12 months) (not passed)
  • Return on equity of 12%+ (5-year average) (not passed)
  • Return on invested capital of 10%+ (5-year average) (no data)
  • Operating margin of 10%+ (5-year average) (passed)
  • Operating margin holding up (last 12 months vs 5 years) (not passed)
Cash generationStrong · 4 of 5
  • Cash earnings positive in almost every year (at most one bad year) (passed)
  • Typical year turns 10%+ of revenue into cash (passed)
  • Latest year at or above the typical year (not passed)
  • Free cash flow positive (last 12 months) (passed)
  • Revenue larger than 5 years ago (passed)
Balance sheetStrong · 5 of 5
  • Debt no larger than equity (passed)
  • Cash and short-term investments exceed debt (passed)
  • Positive shareholders' equity (passed)
  • Debt clearly tagged in the filings (passed)
  • Operating margin above zero (last 12 months) (passed)
Shareholder returnsWeak · 0 of 5
  • Pays a dividend (not passed)
  • Dividend paid in each of the last 5 years (not passed)
  • Dividend grew over 5 years (no data)
  • Pays out 75% or less of earnings (no data)
  • Share count flat or falling over 5 years (not passed)

Flags

This estimate is less than a third of what outside investors' shares were worth on the company's cover page (June 30, 2025): the filings alone probably miss what investors expect (faster growth, margins still changing, or a business that is changing).

How we got this number

In a typical year RGEN kept 16% of its revenue as cash after running and maintaining the business (before interest). We assume revenue shrinks 2.7% a year for five years, then recovers to 2.5% growth by year ten, and discount the cash at 8.8% a year (the 10-year Treasury yield plus 5 points, blended with the cost of its debt). That is worth $23.84 a share today.

Technical details
Model
Discounted cash flow on cash earnings
Cash-earnings margin: typical year (worst / best 3-year stretch)
15.9% (10.1% / 21.8%)
Years used
2018–2025
Revenue growth, years 1–5 (range tested)
-2.7% (-8 to 2%)
Capital needed per $1 of new revenue
$0.21 equipment, $0.29 working capital
Discount rate
8.8%
Revenue base
$0.7B (lower of TTM and last FY)
Debt / cash
$0.6B / $0.9B
Value if investors require Treasury + 3 / + 8 points (we use + 5)
$27.34 / $20.45
If growth after year 10 keeps today's returns
$26.17
Likely range
10th–90th percentile of 4,000 runs with different assumptions
Required return
10-year Treasury 5.15% (2026-11-13) + 5%

What the price assumes

At the last close of $167.89 (Nov 13, 2026), the price is betting on far more than we assume. In our model, no margin we can show would reach it, so we do not print one.

Its typical year
16¢
Its last 3 years
10¢
Its best year
23¢

So the price needs more than a higher margin can give: faster or longer growth than our rules allow, a discount rate below our 8.8%, or something our model leaves out. Our growth rules are cautious: growth is capped at 15% a year and adds no value after year 10.

Typical, best and worst years are from the 8 years we checked in its filings (2018–2025). Everything else stays as described above, including the growth path and the discount rate.

Technical details

Value per share is a straight line in the margin until it reaches zero: value = margin × cash factor − (growth spending + debt and other claims) per share. We solve for the margin that gives the last close, with growth, discount rate, equipment and working capital held as in the main model.

Revenue base $738M. Growth −2.7% for five years, fading to 2.5% by year 10. Discount rate 8.8%. At 15.9¢ the filings-based value is $23.84. Each extra 1¢ of margin adds $1.18 a share. The last close is $167.89, which is $144.05 above the filings-based value, more than any margin we can show would add.

Terminal rule: Growth after year 10 earns only the discount rate, so it adds no value.

Ten years of results

Revenue

$738M in FY2025, up 16% on the year before

FY2016: $105MFY2017: $141MFY2018: $194MFY2019: $270MFY2020: $366MFY2021: $671MFY2022: $802MFY2023: $632MFY2024: $634MFY2025: $738M$500M$1BFY16FY19FY22FY25$738M
Show as table
YearRevenue
FY2016$105M
FY2017$141M
FY2018$194M
FY2019$270M
FY2020$366M
FY2021$671M
FY2022$802M
FY2023$632M
FY2024$634M
FY2025$738M

Cash earnings as a share of sales

13.9% of sales in FY2025

FY2018: 13.7%FY2019: 17.8%FY2020: 21.6%FY2021: 23.2%FY2022: 20.7%FY2023: 7.5%FY2024: 8.8%FY2025: 13.9%0%12%25%FY16FY19FY22FY2514%
Show as table
YearCash earnings as a share of sales
FY2016–
FY2017–
FY201813.7%
FY201917.8%
FY202021.6%
FY202123.2%
FY202220.7%
FY20237.5%
FY20248.8%
FY202513.9%

Shares outstanding

Share count rose 66% over 9 years

FY2016: 34MFY2017: 39MFY2018: 45MFY2019: 49MFY2020: 54MFY2021: 57MFY2022: 57MFY2023: 56MFY2024: 56MFY2025: 57M030M60MFY16FY19FY22FY2556.6M
Show as table
YearShares outstanding
FY201634M
FY201739M
FY201845M
FY201949M
FY202054M
FY202157M
FY202257M
FY202356M
FY202456M
FY202557M

No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-10-30. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13.